Maurizio Fava

Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial

Suresh Durgam, Willie R. Earley, Susan G. Kozauer, Yifan Mo et autres

OBJECTIVE: This phase 3, randomized, double-blind, placebo-controlled trial evaluated lumateperone 42 mg (a simultaneous modulator of serotonin, dopamine, and glutamate neurotransmission) adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) and inadequate ADT response. METHODS: -defined MDD and inadequate …

us (code pays fourni par la source)

Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Antidepressant Tachyphylaxis

Clotilde Guidetti, George I. Papakostas, Luca Pani, Sara De Martin et autres

Antidepressant tolerance/ tachyphylaxis (AT) is defined as initial response (≥ 50% improvement) to antidepressant treatment followed by relapse while on the same adequate dose. The impact of AT as prognostic indicator for response to subsequent antidepressant treatment is unknown. To test the …

us, it, ca (code pays fourni par la source)

Comparative Effectiveness Research Trial for Antidepressant Incomplete and Nonresponders With Treatment Resistant Depression (ASCERTAIN-TRD)

Clotilde Guidetti, Stefania Chaikali, Madhukar H. Trivedi, Richard C. Shelton et autres

This study compared the effects of augmenting antidepressants with aripiprazole or repetitive transcranial magnetic stimulation (rTMS) versus switching to venlafaxine XR/duloxetine on quality of life (QoL) among patients with treatment resistant depression (TRD). In a predefined secondary analysis of a multisite, open-label, …

us, it, ca (code pays fourni par la source)

Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD)

Clotilde Guidetti, Stefania Chaikali, Madhukar H. Trivedi, Richard C. Shelton et autres

us, ca (code pays fourni par la source)

Pre-Pandemic Physical Activity and Early COVID-19 Pandemic Depressive Symptoms in Older Adults

Dennis Muñoz‐Vergara, Howard D. Sesso, Eun-Jung Kim, Maurizio Fava et autres

Importance:Pre-pandemic physical activity (PA) levels may be associated with a lower risk of experiencing depressive symptoms in the context of psychosocial resilience during a global crisis. Objective:To investigate the association between self-reported pre-pandemic PA levels and the risk of experiencing depressive symptoms …

us (code pays fourni par la source)

EEG measures of brain arousal in relation to symptom improvement in patients with major depressive disorder: Results from a randomized placebo-controlled clinical trial

Christine Ulke, Jürgen Kayser, Craig E. Tenke, Roland Mergl et autres

• EEG derived arousal stability is discussed as biomarker for response to antidepressants. • High arousal stability during a 2-min EEG at rest was associated with a better outcome in the sertraline arm, but worse outcome in the placebo arm. • Results …

de, us (code pays fourni par la source)

Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system

Caitlin C. Clements, Víctor M. Castro, Sarah R. Blumenthal, Hannah R. Rosenfield et autres

us (code pays fourni par la source)

Integrating Cognitive Therapy and Pharmacotherapy in the Treatment and Prophylaxis of Depression: A Novel Approach

Joel A. Pava, Maurizio Fava, Janet A. Levenson

Psychiatric clinicians frequently prescribe biologic treatments such as antidepressant medication in combination with psychologic treatments such as psychotherapy. In the present article we propose a model integrating antidepressant treatment with Beck's cognitive therapy, a form of psychotherapy with established efficacy in the …

us (code pays fourni par la source)

Efficacy and Safety of Mirtazapine in Major Depressive Disorder Patients After SSRI Treatment Failure

Maurizio Fava, David L. Dünner, John H. Greist, Sheldon Preskorn et autres

OBJECTIVE: To evaluate the efficacy and safety of mirtazapine in depressed outpatients who have shown nonresponse or intolerance to selective serotonin reuptake inhibitor (SSRI) therapy. METHOD: In this open-label, 8-week study, the efficacy and safety of mirtazapine among 103 outpatients with DSM-IV …

us (code pays fourni par la source)

Timing of Onset of Antidepressant Response With Fluoxetine Treatment

Andrew A. Nierenberg, Amy H. Farabaugh, Jonathan E. Alpert, Johanna Gordon et autres

OBJECTIVE: The purpose of this study was to assess the time until onset of antidepressant response with fluoxetine treatment. METHOD: The authors evaluated 182 outpatients with major depression who had a sustained acute response to fluoxetine treatment. The outpatients received 8 weeks …

us (code pays fourni par la source)

Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study

Khashayar Vakili, Srinivasan S. Pillay, Beny Lafer, Maurizio Fava et autres

us (code pays fourni par la source)

Anxiety disorders in major depression

Maurizio Fava, Meridith A. Rankin, Emma Wright, Jonathan E. Alpert et autres

us (code pays fourni par la source)